Cytoreductive Surgery Plus HIPEC for Metastatic Colon Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

David Ryan, MD, discusses his debate with Paul H. Sugarbaker, MD, from the ASCO session “Intraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer” and how in his view this type of treatment, as presented to the patient, creates a certain dynamic between the surgeon and medical oncologist, one of hope vs reality.

David Ryan, MD, discusses his debate with Paul H. Sugarbaker, MD, from the ASCO session “Intraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer” and how in his view this type of treatment, as presented to the patient, creates a certain dynamic between the surgeon and medical oncologist, one of hope vs reality.

Recent Videos
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Magnetic Resonance Guided Radiation May Be Beneficial in Nonmetastatic PDAC

Tim Cortese
June 25th 2025
Article

Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Data from the phase 3 CABINET trial support the CHMP’s positive opinion of cabozantinib in well-differentiated extra-pancreatic or pancreatic NETs.

Cabozantinib Earns CHMP Recommendation in Pancreatic Neuroendocrine Tumors

Russ Conroy
June 23rd 2025
Article

Data from the phase 3 CABINET trial support the CHMP’s positive opinion of cabozantinib in well-differentiated extrapancreatic or pancreatic NETs.

Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

Roman Fabbricatore
June 22nd 2025
Article

Subgroup analyses from the phase 3 CheckMate649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.